

Q&A with Dr. Vivek B. Shenoy, PhD, MBA, CEO of Renovo Neural, Inc. a Contract Research Organization providing Proof of Concept Testing and Preclinical Neurology Services to the Pharmaceutical Industry



Dr. Vivek B. Shenoy, PhD, MBA
Chief Executive Officer

Renovo Neural, Inc.
www.renovoneural.com

Contact:
Vivek B Shenoy
216-445-4252
vshenoy@renovoneural.com

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFO Magazine

CEOCFO: *Dr. Shenoy, you have been CEO for a little over a year now with Renovo Neural, Inc, for a little over a year now and have a long history in the industry. What appealed to you? What attracted you to Renovo?*

Dr. Shenoy: What interested me? One was the opportunity. Of course this is the first time that I have had the opportunity be a CEO and that is always exciting.

However, what was more intriguing were the unique offerings of Renovo and that we started off as a spin-out of the Cleveland Clinic. The fact that we still have a very strong association with the Cleveland Clinic was very attractive to me.

“Our people are our biggest asset! Renovo prides itself in being early adapters of technology, and in collaborating very closely with our clients to develop unique and customized studies specific to their needs. The whole package makes us a very unique organization, and allows my clients to have the confidence to bring their research to Renovo Neural.”- Dr. Vivek B. Shenoy, PhD, MBA

CEOCFO: *What is the focus at Renovo?*

Dr. Shenoy: We are a CRO – a Contract Research Organization (we are not a clinical research organization). We perform contract research in preclinical situations and are focused largely in the neurology area at the present time. What we do in preclinical research is very vital in that we provide Proof of Concept (POC) testing. We were conceived and born out of the ideas from Dr. Bruce Trapp, who was the founder and Chief Scientific Officer. Dr. Trapp is currently the Chairman of the Department of Neurosciences at the Cleveland Clinic and he continues to be Renovo’s CSO. His strong scientific background, his reputation and presence in the field has enabled us to establish ourselves as leaders in providing preclinical neurology services to the pharmaceutical industry.

CEOCFO: *Who is turning to you for services?*

Dr. Shenoy: Anyone from academic researchers to virtual companies and large pharma companies that have preclinical drugs to test. At the present time our focus has been in neurology – so any company or organization involved in the discovery of molecules or the discovery of substances that could be used in neurology – more specifically in Multiple Sclerosis (MS), and Parkinson’s Disease (PD). Our clients bring their test molecules to us so that we can conduct specific